BRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 Monotherapy

Reuters12-10

Dec 10 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:

RECURSION REPORTS INTERIM PHASE 1 CLINICAL DATA FOR REC-617 MONOTHERAPY, A POTENTIAL BEST-IN-CLASS CDK7 INHIBITOR, WITH ENCOURAGING PATIENT RESPONSE AND FAVORABLE TOLERABILITY
RECURSION PHARMACEUTICALS INC: CONFIRMED PARTIAL RESPONSE IN PLATINUM-RESISTANT OVARIAN CANCER PATIENT
RECURSION PHARMACEUTICALS: 4 PATIENTS DEMONSTRATED A BEST RESPONSE OF STABLE DISEASE FOR UP TO 6 MONTHS OF TREATMENT
RECURSION PHARMACEUTICALS INC: REC-617 WELL-TOLERATED WITH NO DISCONTINUATIONS DUE TO ADVERSE EVENTS
RECURSION PHARMACEUTICALS INC: PLANS TO CONTINUE MONOTHERAPY DOSE ESCALATION AND INITIATE COMBINATION STUDIES IN 1H 2025

Further company coverage: RXRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490069084?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 07:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490069084","market":"us","top_or_hot":-1,"title":"BRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 Monotherapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 Monotherapy</title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span>Recursion Pharmaceuticals Inc <span>RXRX.O</span>:</p><ul><li><p>RECURSION REPORTS INTERIM PHASE 1 CLINICAL DATA FOR REC-617 MONOTHERAPY, A POTENTIAL BEST-IN-CLASS CDK7 INHIBITOR, WITH ENCOURAGING PATIENT RESPONSE AND FAVORABLE TOLERABILITY</p></li><li><p>RECURSION PHARMACEUTICALS INC: CONFIRMED PARTIAL RESPONSE IN PLATINUM-RESISTANT OVARIAN CANCER PATIENT</p></li><li><p>RECURSION PHARMACEUTICALS: 4 PATIENTS DEMONSTRATED A BEST RESPONSE OF STABLE DISEASE FOR UP TO 6 MONTHS OF TREATMENT</p></li><li><p>RECURSION PHARMACEUTICALS INC: REC-617 WELL-TOLERATED WITH NO DISCONTINUATIONS DUE TO ADVERSE EVENTS</p></li><li><p>RECURSION PHARMACEUTICALS INC: PLANS TO CONTINUE MONOTHERAPY DOSE ESCALATION AND INITIATE COMBINATION STUDIES IN 1H 2025</p></li></ul><p>Further company coverage: <span>RXRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 Monotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 Monotherapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 07:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA1NM:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 MonotherapyDec 10 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:RECURSION REPORTS INTERIM PHASE 1 CLINICAL DATA FOR REC-617 ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA1NM:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nFWN3NA1NM:1","article_id":"2490069084","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490069084","pubTimestamp":1733785746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 MonotherapyDec 10 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:RECURSION REPORTS INTERIM PHASE 1 CLINICAL DATA FOR REC-617 MONOTHE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","RXRX":"Recursion Pharmaceuticals, Inc.","BK4548":"巴美列捷福持仓"},"translate_title":"BRIEF-Recursion报告Rec-617单药疗法的中期1期临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":0.9},"content_text":"BRIEF-Recursion Reports Interim Phase 1 Clinical Data For Rec-617 MonotherapyDec 10 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:RECURSION REPORTS INTERIM PHASE 1 CLINICAL DATA FOR REC-617 MONOTHERAPY, A POTENTIAL BEST-IN-CLASS CDK7 INHIBITOR, WITH ENCOURAGING PATIENT RESPONSE AND FAVORABLE TOLERABILITYRECURSION PHARMACEUTICALS INC: CONFIRMED PARTIAL RESPONSE IN PLATINUM-RESISTANT OVARIAN CANCER PATIENTRECURSION PHARMACEUTICALS: 4 PATIENTS DEMONSTRATED A BEST RESPONSE OF STABLE DISEASE FOR UP TO 6 MONTHS OF TREATMENTRECURSION PHARMACEUTICALS INC: REC-617 WELL-TOLERATED WITH NO DISCONTINUATIONS DUE TO ADVERSE EVENTSRECURSION PHARMACEUTICALS INC: PLANS TO CONTINUE MONOTHERAPY DOSE ESCALATION AND INITIATE COMBINATION STUDIES IN 1H 2025Further company coverage: RXRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490069084"}